首页|YAP/TAZ基因调控肿瘤耐药性机制的研究进展

YAP/TAZ基因调控肿瘤耐药性机制的研究进展

扫码查看
目的 了解Yes相关蛋白(Yes-associated protein,YAP)/具有PDZ结合基序的转录共激活因子(transcriptional coactivator with PDZ-binding motif,TAZ)在调控肿瘤耐药中的最新研究进展.方法 在 PubMed、CNKI等数据库中查阅YAP/TAZ在调控肿瘤细胞化学药物治疗、免疫治疗及靶向治疗耐药的相关文献并加以综述.结果 YAP/TAZ参与多种肿瘤对化学药物治疗、免疫治疗及靶向治疗的调控,它可与多种蛋白产生相互作用从而诱导肿瘤耐药的发生,YAP/TAZ信号的失控是引起肿瘤细胞耐药的重要机制.结论 YAP/TAZ与肿瘤细胞耐药关系密切,针对YAP/TAZ调控肿瘤耐药的机制研究可为解决肿瘤耐药提供新的策略和靶点.
Research progress of YAP/TAZ in regulating drug resistance in cancer
Objective To elucidate the latest research progress of Yes-associated protein(YAP)/transcriptional coactivator with PDZ-binding motif(TAZ)in regulating tumor drug resistance.Method The relevant literature on YAP/TAZ in regulating tumor cell chemotherapy,immunotherapy,and targeted therapy resistance was reviewed and summarized in the databases such as PubMed,CNKI,and so on.Results The YAP/TAZ was involved in the resistance regulation of chemotherapy,immunotherapy,and targeted therapy in various human tumors.The YAP/TAZ could interact with various proteins to induce the occurrence of tumor resistance.The imbalance of YAP/TAZ signaling might lead to an important mechanism of tumor cell resistance.Conclusions There is a close relation between YAP/TAZ and tumor cell resistance.Studying the mechanism of YAP/TAZ regulating tumor resistance can provide new strategies and targets for addressing tumor resistance.

YAP/TAZdrug resistancechemotherapyimmunotherapytargeted therapy

周伟、刘涛

展开 >

华中科技大学同济医学院附属协和医院消化肿瘤外科(武汉 430022)

YAP/TAZ 耐药性 化学药物治疗 免疫治疗 靶向治疗

吴阶平医学基金会临床科研专项

320.6750.2023-19-14

2024

中国普外基础与临床杂志
四川大学华西医院

中国普外基础与临床杂志

CSTPCD
影响因子:0.858
ISSN:1007-9424
年,卷(期):2024.31(3)
  • 73